Denali Therapeutics, Inc. (DNLI)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$22.28-2.28%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · DNLI
How strong the business is — where it ranks within its sector on capital efficiency and cash generation, and how well management has been executing.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
A guidance track record builds as the company issues and delivers on guidance.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
Execute and expand commercial launch of AVLAYAH, the first FDA-approved TV-enabled medicine, with revenue growth and payer coverage expansion.
Stated as a priority in 2 of last 2 quarters. AVLAYAH launched in Q1 2026 with first patients treated and generated $3.6 million net product revenue in Q2 2026. Guidance projects Q3 revenue between $10.0 million and $12.0 million. Payer coverage and commercial infrastructure expanded rapidly. The trajectory shows delivering commercial growth consistent with management's stated priorities.
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 1 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated neutral grew net income 51% of the time over the next year (vs 41% for the rest of the cohort, n=13363).
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
“AVLAYAH generated $3.6 million in net product revenue in its first full quarter of commercial availability.”
“FDA approved AVLAYAH and commercial launch underway with first patients treated in April 2026.”
Continue clinical development of DNL593 for FTD-GRN after regaining full rights, with results expected by end of 2026.
Stated as a priority in 3 of last 3 quarters. Management regained full rights to DNL593 in early 2026 and planned to report Phase 1/2 results by end of 2026. In Q2 2026, management updated timing to 2027 to allow longer observation. The trajectory shows continued clinical development with timing adjustment but consistent focus on data reporting.
“Denali continues to advance DNL593 in the ongoing Phase 1/2 study with results expected in 2027, updated from prior expectation of end 2026.”
“Advancing DNL593 in Phase 1/2 study for FTD-GRN after regaining full rights, with data expected by end of 2026.”
“Received notification from Takeda terminating collaboration; Denali to independently advance DNL593 with results expected by end 2026.”
Progress multiple pipeline programs enabled by the TransportVehicle platform across lysosomal storage and neurodegenerative diseases.
Stated as a priority in 2 of last 2 quarters. Management highlighted advancement of two Alzheimer's disease programs into clinical development and ongoing IND-enabling stage programs. The pipeline progression is consistent with management's stated strategic focus on expanding the TransportVehicle platform portfolio.
“Advanced TransportVehicle portfolio with two Alzheimer's disease programs now in clinical development.”
“Dosed first patients with Oligonucleotide TV-enabled DNL628 targeting tau for Alzheimer's disease; multiple IND-enabling programs ongoing.”
Maintain financial stability through capital management including royalty funding agreements and monetization of assets like the Priority Review Voucher.
Stated as a priority in 3 of last 3 quarters. Management completed a $195 million sale of the Priority Review Voucher in July 2026, increasing pro forma cash to over $1.1 billion. Earlier in 2026, $200 million was received from a synthetic royalty funding agreement. The financial management trajectory shows delivering capital structure strengthening consistent with stated priorities.
“Received $195 million gross proceeds from sale of Priority Review Voucher in July 2026, increasing pro forma cash to over $1.1 billion.”
“Received $200 million gross proceeds from synthetic royalty funding agreement with Royalty Pharma in March 2026.”
“Managing financial obligations and capital structure including royalty funding agreements.”
Cease development of BIIB122 (DNL151) in idiopathic Parkinson's disease following Phase 2b LUMA study failure, continue Phase 2a BEACON study in LRRK2 variant carriers.
Newly stated in 2026-Q2 period. Management announced discontinuation of BIIB122 development in idiopathic Parkinson's disease after Phase 2b LUMA study failed to meet endpoints. The Phase 2a BEACON study in LRRK2 variant carriers continues. This reflects a strategic shift based on clinical data.
Over the trailing year it converted 0.98x of net income into operating cash flow.
Most sensitive to the broad stock market.
Not enough signal to read sensitivity to the US dollar, real (inflation-adjusted) rates, long-term interest rates, Fed net liquidity (low R² over the window).
9 material management or governance events in the past 24 months, led by M&A activity. Historically, Health Care names rated neutral grew net income 53% of the time over the next year (vs 49% for the rest of the cohort, n=5275).
Not investment advice. As of 2026-09-04.